{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T17:13:43Z","timestamp":1793121223924,"version":"4.5.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"vor","delay-in-days":39,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Precis. Onc."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Immunotherapy has significantly improved the treatment of metastatic solid tumors; however, detecting early signs of response to enable timely intervention for resistant tumors remains challenging. A blood-only circulating tumor DNA (ctDNA) test may provide a rapid assessment of tumor response without reliance on matched tumor tissue. We applied a tissue-agnostic, genome-wide methylation enrichment assay, based on cell-free methylated DNA immunoprecipitation and high-throughput sequencing (cfMeDIP-seq), to plasma samples from patients in a phase 2 trial evaluating pembrolizumab across multiple solid tumors (NCT02644369). A decrease in ctDNA from baseline to pre-cycle 3 was significantly associated with higher objective response and clinical benefit rates and longer progression-free and overall survival in univariate analyses, with these associations remaining significant in multivariable models except for overall survival. These results validate a commercial-grade, tissue-agnostic plasma cfDNA methylation platform for immunotherapy response monitoring, which may facilitate earlier, more informed treatment decisions and improve patient outcomes.<\/jats:p>","DOI":"10.1038\/s41698-026-01327-y","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T15:48:29Z","timestamp":1770997709000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Clinical validation of a tissue-agnostic genome-wide methylome enrichment assay to monitor response to pembrolizumab"],"prefix":"10.1038","volume":"10","author":[{"given":"Eric Y.","family":"Stutheit-Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongqi","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Collin A.","family":"Melton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth D.","family":"Lightbody","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Hinterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yarong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Owen","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo V.","family":"Sosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy B.","family":"Provance","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abel","family":"Licon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihui Amy","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albiruni R.","family":"Abdul Razak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Spreafico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe L.","family":"Bedard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron R.","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Lheureux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela S.","family":"Ohashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott V.","family":"Bratman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian A.","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel D.","family":"De Carvalho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Renee","family":"Hartman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lillian L.","family":"Siu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Sanz-Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,13]]},"reference":[{"key":"1327_CR1","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/s41571-022-00600-w","volume":"19","author":"DB Johnson","year":"2022","unstructured":"Johnson, D. B., Nebhan, C. A., Moslehi, J. J. & Balko, J. M. Immune-checkpoint inhibitors: long-term implications of toxicity. Nat. Rev. Clin. Oncol. 19, 254\u2013267 (2022).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1327_CR2","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1016\/j.cell.2023.03.006","volume":"186","author":"P Sharma","year":"2023","unstructured":"Sharma, P. et al. Immune checkpoint therapy-current perspectives and future directions. Cell 186, 1652\u20131669 (2023).","journal-title":"Cell"},{"key":"1327_CR3","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1158\/2159-8290.CD-20-1680","volume":"11","author":"P Sharma","year":"2021","unstructured":"Sharma, P. et al. The next decade of immune checkpoint therapy. Cancer Discov. 11, 838\u2013857 (2021).","journal-title":"Cancer Discov."},{"key":"1327_CR4","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s40425-019-0602-4","volume":"7","author":"D Bedognetti","year":"2019","unstructured":"Bedognetti, D. et al. Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop. J. Immunother. Cancer 7, 131 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"1327_CR5","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/s41568-024-00705-7","volume":"24","author":"AM Holder","year":"2024","unstructured":"Holder, A. M. et al. Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours. Nat. Rev. Cancer 24, 498\u2013512 (2024).","journal-title":"Nat. Rev. Cancer"},{"key":"1327_CR6","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1200\/EDBK_200643","volume":"38","author":"E Borcoman","year":"2018","unstructured":"Borcoman, E., Nandikolla, A., Long, G., Goel, S. & Le Tourneau, C. Patterns of response and progression to immunotherapy. Am. Soc. Clin. Oncol. Educ. Book 38, 169\u2013178 (2018).","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"1327_CR7","doi-asserted-by":"publisher","first-page":"3541","DOI":"10.1200\/JCO.2015.61.6870","volume":"33","author":"VL Chiou","year":"2015","unstructured":"Chiou, V. L. & Burotto, M. Pseudoprogression and immune-related response in solid tumors. J. Clin. Oncol. 33, 3541\u20133543 (2015).","journal-title":"J. Clin. Oncol."},{"key":"1327_CR8","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1148\/rg.352140121","volume":"35","author":"JJ Kwak","year":"2015","unstructured":"Kwak, J. J., Tirumani, S. H., Van den Abbeele, A. D., Koo, P. J. & Jacene, H. A. Cancer immunotherapy: imaging assessment of novel treatment response patterns and immune-related adverse events. Radiographics 35, 424\u2013437 (2015).","journal-title":"Radiographics"},{"key":"1327_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-025-00876-y","volume":"9","author":"A Bartolomucci","year":"2025","unstructured":"Bartolomucci, A. et al. Circulating tumor DNA to monitor treatment response in solid tumors and advance precision oncology. NPJ Precis. Oncol. 9, 84 (2025).","journal-title":"NPJ Precis. Oncol."},{"key":"1327_CR10","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1158\/0008-5472.CAN-21-1718","volume":"82","author":"JC Stadler","year":"2022","unstructured":"Stadler, J. C. et al. Current and future clinical applications of ctDNA in immuno-oncology. Cancer Res. 82, 349\u2013358 (2022).","journal-title":"Cancer Res."},{"key":"1327_CR11","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1038\/nature25161","volume":"554","author":"C Abbosh","year":"2018","unstructured":"Abbosh, C. et al. Corrigendum: phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature 554, 264 (2018).","journal-title":"Nature"},{"key":"1327_CR12","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1158\/1078-0432.CCR-24-3472","volume":"31","author":"MJ Elliott","year":"2025","unstructured":"Elliott, M. J. et al. Ultrasensitive detection and monitoring of circulating tumor DNA using structural variants in early-stage breast cancer. Clin. Cancer Res. 31, 1520\u20131532 (2025).","journal-title":"Clin. Cancer Res."},{"key":"1327_CR13","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/s43018-020-0043-5","volume":"1","author":"DW Cescon","year":"2020","unstructured":"Cescon, D. W., Bratman, S. V., Chan, S. M. & Siu, L. L. Circulating tumor DNA and liquid biopsy in oncology. Nat. Cancer 1, 276\u2013290 (2020).","journal-title":"Nat. Cancer"},{"key":"1327_CR14","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/j.cell.2014.06.049","volume":"158","author":"KA Hoadley","year":"2014","unstructured":"Hoadley, K. A. et al. Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. Cell 158, 929\u2013944 (2014).","journal-title":"Cell"},{"key":"1327_CR15","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/s41586-022-05580-6","volume":"613","author":"N Loyfer","year":"2023","unstructured":"Loyfer, N. et al. A DNA methylation atlas of normal human cell types. Nature 613, 355\u2013364 (2023).","journal-title":"Nature"},{"key":"1327_CR16","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1016\/j.ccell.2022.10.022","volume":"40","author":"A Jamshidi","year":"2022","unstructured":"Jamshidi, A. et al. Evaluation of cell-free DNA approaches for multi-cancer early detection. Cancer Cell 40, 1537\u20131549 e1512 (2022).","journal-title":"Cancer Cell"},{"key":"1327_CR17","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.annonc.2020.02.011","volume":"31","author":"MC Liu","year":"2020","unstructured":"Liu, M. C. et al. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. Ann. Oncol. 31, 745\u2013759 (2020).","journal-title":"Ann. Oncol."},{"key":"1327_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-07466-6","volume":"9","author":"J Moss","year":"2018","unstructured":"Moss, J. et al. Comprehensive human cell-type methylation atlas reveals origins of circulating cell-free DNA in health and disease. Nat. Commun. 9, 5068 (2018).","journal-title":"Nat. Commun."},{"key":"1327_CR19","doi-asserted-by":"publisher","first-page":"2749","DOI":"10.1038\/s41596-019-0202-2","volume":"14","author":"SY Shen","year":"2019","unstructured":"Shen, S. Y., Burgener, J. M., Bratman, S. V. & De Carvalho, D. D. Preparation of cfMeDIP-seq libraries for methylome profiling of plasma cell-free DNA. Nat. Protoc. 14, 2749\u20132780 (2019).","journal-title":"Nat. Protoc."},{"key":"1327_CR20","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/s41586-018-0703-0","volume":"563","author":"SY Shen","year":"2018","unstructured":"Shen, S. Y. et al. Sensitive tumour detection and classification using plasma cell-free DNA methylomes. Nature 563, 579\u2013583 (2018).","journal-title":"Nature"},{"key":"1327_CR21","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.annonc.2024.08.2348","volume":"36","author":"G Liu","year":"2025","unstructured":"Liu, G. et al. Clinical validation of a tissue-agnostic genome-wide methylome enrichment molecular residual disease assay for head and neck malignancies. Ann. Oncol. 36, 108\u2013117 (2025).","journal-title":"Ann. Oncol."},{"key":"1327_CR22","doi-asserted-by":"publisher","first-page":"4230","DOI":"10.1158\/1078-0432.CCR-21-0110","volume":"27","author":"JM Burgener","year":"2021","unstructured":"Burgener, J. M. et al. Tumor-naive multimodal profiling of circulating tumor DNA in head and neck squamous cell carcinoma. Clin. Cancer Res. 27, 4230\u20134244 (2021).","journal-title":"Clin. Cancer Res."},{"key":"1327_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34012-2","volume":"13","author":"S Chen","year":"2022","unstructured":"Chen, S. et al. The cell-free DNA methylome captures distinctions between localized and metastatic prostate tumors. Nat. Commun. 13, 6467 (2022).","journal-title":"Nat. Commun."},{"key":"1327_CR24","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1038\/s41591-020-0933-1","volume":"26","author":"PV Nuzzo","year":"2020","unstructured":"Nuzzo, P. V. et al. Detection of renal cell carcinoma using plasma and urine cell-free DNA methylomes. Nat. Med. 26, 1041\u20131043 (2020).","journal-title":"Nat. Med."},{"key":"1327_CR25","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1158\/2159-8290.CD-23-1060","volume":"14","author":"EY Stutheit-Zhao","year":"2024","unstructured":"Stutheit-Zhao, E. Y. et al. Early changes in tumor-naive cell-free methylomes and fragmentomes predict outcomes in pembrolizumab-treated solid tumors. Cancer Discov. 14, 1048\u20131063 (2024).","journal-title":"Cancer Discov."},{"key":"1327_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2022.105487","volume":"25","author":"S Ul Haq","year":"2022","unstructured":"Ul Haq, S. et al. Cell-free DNA methylation-defined prognostic subgroups in small-cell lung cancer identified by leukocyte methylation subtraction. iScience 25, 105487 (2022).","journal-title":"iScience"},{"key":"1327_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.crmeth.2022.100294","volume":"2","author":"SL Wilson","year":"2022","unstructured":"Wilson, S. L. et al. Sensitive and reproducible cell-free methylome quantification with synthetic spike-in controls. Cell Rep. Methods 2, 100294 (2022).","journal-title":"Cell Rep. Methods"},{"key":"1327_CR28","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1093\/neuonc\/noac264","volume":"25","author":"JA Zuccato","year":"2023","unstructured":"Zuccato, J. A. et al. Cerebrospinal fluid methylome-based liquid biopsies for accurate malignant brain neoplasm classification. Neuro Oncol. 25, 1452\u20131460 (2023).","journal-title":"Neuro Oncol."},{"key":"1327_CR29","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s40425-019-0541-0","volume":"7","author":"DL Clouthier","year":"2019","unstructured":"Clouthier, D. L. et al. An interim report on the investigator-initiated phase 2 study of pembrolizumab immunological response evaluation (INSPIRE). J. Immunother. Cancer 7, 72 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"1327_CR30","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1158\/1538-7445.AM2023-1030","volume":"83","author":"BH Park","year":"2023","unstructured":"Park, B. H. et al. Development of a genome-wide methylome enrichment platform for multi-cancer early detection (MCED). Cancer Res. 83, 1030\u20131030 (2023).","journal-title":"Cancer Res."},{"key":"1327_CR31","doi-asserted-by":"publisher","first-page":"5024","DOI":"10.1158\/1538-7445.AM2024-5024","volume":"84","author":"SY Shen","year":"2024","unstructured":"Shen, S. Y. et al. Analytical performance of a genome-wide methylome enrichment platform to detect minimal residual disease from plasma-derived cell-free DNA. Cancer Res. 84, 5024\u20135024 (2024).","journal-title":"Cancer Res."},{"key":"1327_CR32","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1038\/s43018-020-0096-5","volume":"1","author":"SV Bratman","year":"2020","unstructured":"Bratman, S. V. et al. Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab. Nat. Cancer 1, 873\u2013881 (2020).","journal-title":"Nat. Cancer"},{"key":"1327_CR33","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1158\/2767-9764.CRC-25-0151","volume":"5","author":"SI Liang","year":"2025","unstructured":"Liang, S. I. et al. Methylation-based ctDNA tumor fraction changes predict long-term clinical benefit from immune checkpoint inhibitors in RADIOHEAD, a real-world pan-cancer study. Cancer Res. Commun. 5, 1384\u20131395 (2025).","journal-title":"Cancer Res. Commun."},{"key":"1327_CR34","doi-asserted-by":"publisher","first-page":"eaar3593","DOI":"10.1126\/science.aar3593","volume":"362","author":"R Cristescu","year":"2018","unstructured":"Cristescu, R. et al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science 362, eaar3593 (2018).","journal-title":"Science"},{"key":"1327_CR35","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin, J. et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373, 23\u201334 (2015).","journal-title":"N. Engl. J. Med."},{"key":"1327_CR36","doi-asserted-by":"crossref","unstructured":"Yarchoan, M. et al. PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers. JCI Insights. 4, e126908 (2019).","DOI":"10.1172\/jci.insight.126908"},{"key":"1327_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-016-0267-3","volume":"16","author":"M van Smeden","year":"2016","unstructured":"van Smeden, M. et al. No rationale for 1 variable per 10 events criterion for binary logistic regression analysis. BMC Med. Res. Methodol. 16, 163 (2016).","journal-title":"BMC Med. Res. Methodol."},{"key":"1327_CR38","doi-asserted-by":"publisher","first-page":"1103797","DOI":"10.3389\/fonc.2023.1103797","volume":"13","author":"AD Johnston","year":"2023","unstructured":"Johnston, A. D., Ross, J. P., Ma, C., Fung, K. Y. C. & Locke, W. J. Epigenetic liquid biopsies for minimal residual disease, what\u2019s around the corner?. Front. Oncol. 13, 1103797 (2023).","journal-title":"Front. Oncol."},{"key":"1327_CR39","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","volume":"378","author":"L Gandhi","year":"2018","unstructured":"Gandhi, L. et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N. Engl. J. Med. 378, 2078\u20132092 (2018).","journal-title":"N. Engl. J. Med."},{"key":"1327_CR40","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41416-024-02895-1","volume":"132","author":"HH Hektoen","year":"2025","unstructured":"Hektoen, H. H. et al. Real-world evidence for pembrolizumab in non-small cell lung cancer: a nationwide cohort study. Br. J. Cancer 132, 93\u2013102 (2025).","journal-title":"Br. J. Cancer"},{"key":"1327_CR41","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1200\/JCO.21.00174","volume":"39","author":"M Reck","year":"2021","unstructured":"Reck, M. et al. Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score \u2265 50. J. Clin. Oncol. 39, 2339\u20132349 (2021).","journal-title":"J. Clin. Oncol."},{"key":"1327_CR42","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck, M. et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N. Engl. J. Med. 375, 1823\u20131833 (2016).","journal-title":"N. Engl. J. Med."},{"key":"1327_CR43","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1002\/sim.1047","volume":"21","author":"G Heinze","year":"2002","unstructured":"Heinze, G. & Schemper, M. A solution to the problem of separation in logistic regression. Stat. Med. 21, 2409\u20132419 (2002).","journal-title":"Stat. Med."}],"container-title":["npj Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01327-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01327-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01327-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T16:03:45Z","timestamp":1774368225000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01327-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,13]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1327"],"URL":"https:\/\/doi.org\/10.1038\/s41698-026-01327-y","relation":{},"ISSN":["2397-768X"],"issn-type":[{"value":"2397-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,13]]},"assertion":[{"value":"11 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.D.D.C. and S.V.B. are cofounders of Adela, serve in leadership positions, and own Adela shares. This arrangement has been reviewed and approved by the University Health Network in accordance with its conflict-of-interest policies. In addition, the University Health Network owns Adela equities. D.D.D.C. and S.V.B. are inventors in multiple patents related to cfDNA methylation profiling technology licensed to Adela and applied in this manuscript. D.D.D.C. is an inventor on PCT\/CA2017\/000108 (assignee, University Health Network) and PCT\/CA2020\/051507 (assignees, University Health Network, Van Andel Research Institute). D.D.D.C. and S.V.B. are inventors on PCT\/CA2018\/000141 (assignee, University Health Network) and PCT\/CA2021\/050842 (assignee, University Health Network). S.V.B. is also an inventor on a patent related to cfDNA mutation analysis technology outside of this work that has been licensed to Roche [PCT\/US2014\/025020 (assignee, Stanford University)]. E.Y.S-Z. provided consulting services for Adela. A.R. reports grants from Merck during the conduct of the study; grants from Adaptimmune, Bayer, GlaxoSmithKline, Medison, Inhibrx; research funding from Deciphera, Karyopharm Therapeutics, Pfizer, Roche\/Genentech, Bristol Myers Squibb, MedImmune, Amgen, GlaxoSmithKline, Blueprint Medicines, Merck, AbbVie, Adaptimmune, Iterion Therapeutics, Neoleukin Therapeutics, Daiichi Sankyo, Symphogen, Rain Therapeutics, and Boehringer Ingelheim; and personal fees from Boehringer Ingelheim, Merck, Eli Lilly, and Medison outside the submitted work. A.S. reports grants and personal fees from Merck, BMS, grants from Novartis, Symphogen, AstraZeneca\/Medimmune, Bayer, Surface Oncology, Janssen Oncology\/Johnson & Johnson, Roche, Regeneron, Alkermes, Array Biopharma\/Pfizer, GSK, NuBiyota, Oncorus, Treadwell, Amgen, ALX Oncology, Genentech, Seagen, Servier, Incyte, and Gilead outside the submitted work. P.S.O. is on scientific advisory boards for Providence Therapeutics, Tikva Allocell, and Rondo Therapeutics, Inc., and holds a sponsored research agreement with Providence Therapeutics. A.H. receives honoraria from Merck, Janssen, Astellas, Pfizer, Bayer; serves a consulting or advisory role for Astellas, Merck, Bayer, Eisai, Janssen; has institutional research funding from Merck, Bristol Myers Squibb, Janssen, Advancell, AVEO, SEAGEN, Macrogenics, Tyra-Biosciences, FUSION, Full Life Technologies; and has travel grants from Bayer. P.B. receives honoraria from Boehringer Ingelheim and research funding from Bristol Myers Squibb, Sanofi, AstraZeneca, Genentech\/Roche, GlaxoSmithKline, Novartis, Merck, Seattle Genetics, Lilly, Amgen, Bicara, Zymeworks, Medicenna, Bayer, Takeda, Gilead Sciences, LegoChem Biosciences, Boehringer Ingelheim, ProteinQure, Daiichi Sankyo\/UCB Japan. A.-R.H is a cofounder, chief medical officer, and serves in a leadership position at Adela; and owns Adela shares and reports Illumina shares. E.S.G. reports a relationship with GSK that includes consulting fees and grants from GSK and Rgenta Therapeutics. All Adela authors (Y.Z., C.A.M., E.D.L., M.A.H., Y.W., O.H., E.V.S., J.B.P., J.Z., A.L., A.W., B.A.A., J.Z.) report full-time employment and Adela stock options. L.L.S. acts as a consultant\/advisory role for Merck, Pfizer, AstraZeneca, Roche, GSK, Voronoi, Arvinas, Navire, Relay, Marengo, Daiichi Sankyo, Amgen, LTZ Therapeutics, Tubulis, Marengo, Nerviano, Pangea, Velavigo, and Incyte; receives grant\/research support from Merck, Novartis, Bristol Myers Squibb, Pfizer\/SeaGen, Boerhinger Ingelheim, GlaxoSmithKline, Roche\/Genentech, AstraZeneca\/Medimmune, Bayer, Abbvie, Amgen, EMD Serono, Daiichi Sankyo, Gilead, Marengo, Incyte; is a founder and serves in a leadership position at Treadwell Therapeutics. All other authors declare no competing financial or non-financial competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"129"}}